Abstract
Background: The ultimate goal of mitral valve surgery in younger women
is to extend life expectancy and improve quality of life. Mitral valve
replacement prosthesis in the middle-aged women is a difficult choice
between the lifelong anticoagulation of a mechanical prosthesis versus a
limited long-term durability of the bioprosthesis. The current trend
towards reducing the women age for selection of the mitral bioprosthesis
over a mechanical prosthesis lead to a dilemma for younger women
decision making.1,2 The aim of this study is to compare the clinical
out-comes after mitral valve bioprosthesis versus mechanical prosthesis
in younger women population when mitral valves repair not feasible or
unsuitable. Methods: A single-centre prospective non randomized
registration of all women patients undergoing Mitral Valve Replacement
at our center from January 2010 to February 2020 established. Results:
Between January 2010 and February 2020, 355 female patients underwent
mitral valve replacement at our center, 174 female patients of them had
mitral valve replacement with mitral bioprosthesis (Mb) and 181 female
patients of them had mitral valve replacement with mitral mechanical
(Mm) prosthesis. Our study proved that the use of anticoagulation among
the Mm young women associated with a remarkable risk of postoperative
bleeding, abortion and increase frequency of the pregnancy related
complication of the anticoagulation (p=< 0.0001), moreover,
there is a considerable survival benefits for younger women patients
received Mb(p= 0.0001). Conclusions: These data confirm that the impulse
for the use of mitral bioprosthesis for young women population has been
great with an astonishing survival benefits.